News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Kunal Jobanputra: Exciting times in HER2 mutant NSCLC space with Zongertinib
Kunal Jobanputra/LinkedIn
Apr 30, 2025, 09:08

Kunal Jobanputra: Exciting times in HER2 mutant NSCLC space with Zongertinib

Kunal Jobanputra, Consultant Medical Oncologist at Saifee Hospital, shared a post on X:

“Exciting times in HER2 mutant NSCLC space with Zongertinib
Let’s review the data of other molecules –
  • Trastuzumab Deruxtecan (T-DXd) DESTINY-Lung01 (6.4 mg/kg)55% ORR , 9.3m DoR , 8.2m PFS 46% grade ≥3 AEs , 26% ILD
  • DESTINY-Lung02 (5.4 mg/kg)49% ORR , 9.9m PFS . 39% grade ≥3 AEs , 13% ILD (1 fatal) . DESTINY-Lung04 explores first-line use .
  • Trastuzumab Rezetecan (SHR-A1811) : Phase 2 →73% ORR , 11.5m PFS . 62% grade ≥3 AEs, 7% ILD.
  • Pan-HER TKIs : Pyrotinib (19-30% ORR) & poziotinib (27-28% ORR) effective but toxic—diarrhea (17-26%), rash (47-49% with poziotinib)
  • BAY 2927088 : SOHO-0172% ORR , 7.5m PFS . HER2-selective, 25% grade 3 diarrhea”

More posts featuring Kunal Jobanputra

cancer Kunal Jobanputra Lung cancer NSCLC OncoDaily Oncology trastuzumab Zongertinib
Special Coverage
Science
Apr 30, 2025, 09:09
Yüksel Ürün: New era for HER2-mutant lung cancer!
Science
Apr 30, 2025, 09:08
Kunal Jobanputra: Exciting times in HER2 mutant NSCLC space with Zongertinib
Science
Apr 30, 2025, 09:03
Myeloma Paper of the Day, April 30th, suggested by Robert Orlowski
Blog
Apr 30, 2025, 09:02
Amalya Sargsyan: Our abstract on endpoints in G/GEJ trials was selected for a Poster presentation at ESMO GI 2025
Blog
Apr 30, 2025, 08:52
Julie R. Gralow Discusses Grant Management Support for Aspiring Grantmakers
Science
Apr 30, 2025, 08:50
Updates from AACR25 by Amol Akhade
Science
Apr 30, 2025, 08:49
Rashid Lui: Our latest study on alcohol-attributable cancer is out
Blog
Apr 30, 2025, 08:44
Alique Topalian: Honored to present my abstract at AACR Scientist - Survivor Program
Blog
Apr 30, 2025, 08:37
Raphael E. Cuomo: Risk of death increased over twenty-fold in colon cancer patients with cannabis use disorder
Science
Apr 30, 2025, 08:30
Deepak Gupta: Delineating the recurrent laryngeal nerve as an organ at risk
Blog
Apr 30, 2025, 08:30
Aruni Ghose: Clinical Entrepreneurship is still a space where Mentors and Mentees can work and support each other
Blog
Apr 30, 2025, 08:26
Cristiane Decat Bergerot Receives 2025 Noemi Fisman Award for Lifetime Clinical Excellence - IPOS